reveromycin a

Reveromycin A is the major component of a complex of spiroketal antibiotics isolated from Streptomyces sp. It inhibits the mitogenic activity of epidermal growth factor in Balb/MK cells (IC50 = 0.7 μg/ml), displays antiproliferative activity against human KB and K562 tumor cell lines (IC50s = 1.9 and 1.6 μg/ml, respectively), and demonstrates antifungal activity against C. albicans (MIC = 2 μg/ml at pH 3). Reveromycin A also has been shown to inhibit bone resorption by inducing apoptosis in osteoclasts with an IC50 value of 0.7 μM.

Reveromycin C is a polyketide compound originally isolated from Streptomyces, exhibiting antifungal activity against Candida albicans with a MIC of 2.0 μg/mL at pH 3 and >500 μg/mL at pH 7.4. It inhibits EGF-induced mitogenic activity in Balb/MK mouse epidermal cell lines. Additionally, it reverses the morphology of sarcoma virus-transformed NRK rat kidney cells (EC50 = 1.58 μg/mL) and inhibits the proliferation of KB cells and K562 human chronic myelogenous leukemia cells (IC50 = 2.0 μg/mL for both).

Reveromycin D is a bacterial metabolite originally isolated from Streptomyces. It inhibits EGF-induced mitogenic activity in Balb/MK cells and exhibits pH-dependent antifungal activity against C. albicans [MICs = 2 and >500 μg/ml at pH 3 and 7.4, respectively]. Reveromycin D also inhibits the proliferation of KB and K562 cells [IC50s = 1.6 and 1.3 μg/ml, respectively].

Reveromycin B is a spiroketal bacterial metabolite originally isolated from Streptomyces. It inhibits EGF-induced mitogenic activity in Balb/MK cells (IC50 = 6 μg/ml) and exhibits pH-dependent antifungal activity against C. albicans [MICs = 15.6 and >500 μg/ml at pH 3.0 and 7.4, respectively]. Unlike reveromycin A and reveromycin C, reveromycin B does not inhibit the proliferation of KB and K562 cells.